The University of Central Oklahoma, often referred to as UCO, is a coeducational public university located in Edmond, Oklahoma. The university is the third largest in Oklahoma, with more than 17,000 students and approximately 434 full-time and 400 adjunct faculty. Founded in 1890, the University of Central Oklahoma was one of the first institutions of higher learning to be established in what would become the state of Oklahoma, making it one of the oldest universities in the southwest region of the United States of America.It is home to the American branch of the British Academy of Contemporary Music in Downtown Oklahoma City, directed by noted indie music agent and manager Scott Booker. The Environmental Protection Agency recognized the University of Central Oklahoma as the 2009-2010 Individual Conference Champion for using more green power than any other school in the Lone Star Conference. Wikipedia.
News Article | April 11, 2017
Hollywood, April 11, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC:ETST OTCBB:ETST $ETST OTC PINK:ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc., are proud to announce that they will be targeting breast cancer and other women’s health issues with their latest cannabis CBD-based (Indutrial Hemp) pharmaceutical drug development and research initiatives. At the monthly Scientific Advisory Board development meeting on April 4th, attended by Dr. Chandra Panchal, Dr. Domenico Fuoco, Dr. Moutih Rafei, CEO/CSO Dr. Michel Aubé, and representatives of Smart Medicine, Inc., the group decided that their drug development initiative should target breast cancer and other women’s health issues. Cannabis-based treatments have proven to be tremendously effective in treating various forms of cancer, including breast cancer, and Dr. Michel Aubé has years of expertise in this specific niche. With the new direction established, the company has re-focused on several initiatives that will benefit the health of women worldwide. Around the world, women suffer from lack of access to healthcare, both for economic and political reasons, and an inability to take charge of their own health and healthcare. ETST is committed to developing products and services that give women easier access and more control over specific health issues that impact their lives. The company is launching an in-depth study of cannabidiol’s known, unique anti-proliferative effect on breast cancer cells. CEO and Chief Scientific Officer Dr. Michel Aubé will leverage his expertise in this subject, having conducted research on deciphering the mechanism of action of organochlorine on breast cancer cells in his doctorate studies, to lead the group through the drug development pipeline. His previous work resulted in this scientific paper regarding breast cancer: https://www.ncbi.nlm.nih.gov/pubmed/18275596 ETST’s goal is to bring generic pharmaceutical breast cancer and chemo-prevention drugs to market, making them affordable and available to women around the globe. Several of the company’s immediate drug development projects will target breast and ovarian cancers, allowing that important work to benefit from an established in vitro and in vivo experimental infrastructure. Dr. Moutih and Dr. Aube will plan all in vitro and in vivo experiments and Dr. Rafei’s will supervise all experimental procedures. The company’s relationships with Dr. Rafei’s and Smart Medicine will allow it to apply for public and private research grants to engage in R&D to: Additionally, ETST is working on building a strategic partnership with Connexions Commerciales Internationales C.T. Inc., a company focused on hormonal replacement therapies. As previously announced, https://globenewswire.com/news-release/2017/03/27/945536/0/en/Earth-Science-Tech-Inc-Announces-Timeline-Projection-for-its-MSN-2-Medical-Device-and-Partnership-Negotiations-for-its-Cannabis-CBD-Based-Generic-Drugs-Medical-Device-Distribution.html. Many of their generic drugs will also be targeted to women health issues. ETST’s other subsidiary, Earth Science Pharmaceutical Inc., is launching its first product, a medical device that will empower women to take an active role to protect themselves from the long-term medical problems caused by the Sexually Transmitted Infections chlamydia and gonorrhea. ETST continuously plans on updating its shareholders on the above mentioned studies as further progress and development occurs. About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
University of Central Oklahoma | Date: 2016-01-29
A system for guiding and evaluating physical positioning, orientation and motion of the human body, comprising: a cloud computing-based subsystem including an artificial neural network and spatial position analyzer said cloud computing-based subsystem adapted for data storage, management and analysis; at least one motion sensing device wearable on the human body, said at least one motion sensing device adapted to detect changes in at least one of spatial position, orientation, and rate of motion; a mobile subsystem running an application program (app) that controls said at least one motion sensing device, said mobile subsystem adapted to capture activity data quantifying said changes in at least one of spatial position, orientation, and rate of motion, said mobile subsystem further adapted to transfer said activity data to said cloud computing-based subsystem, wherein said cloud computing-based subsystem processes, stores, and analyzes said activity data.
University of Central Oklahoma | Date: 2016-06-21
The present invention provides a process by which both non-tissue engineered and tissue engineered cartilaginous-like structures can be fabricated. The process of the present invention provides a method to produce electrospun nanofiber-anchored NP gels. The present invention provides a functional design for novel engineered IVD. The present invention provides a method for fabrication of both non-tissue and tissue engineered IVDs. These cartilaginous-like structures can be used to produce replacements for degenerated natural IVD. The method of the present invention uses electrospun PCL nanofiber mesh to anchor the NP. The method of the present invention can create angle-ply AF structure around the circumference of NP to mimic the architecture of native IVD. The method of the present invention anchors the top and bottom sides of NP by using non-woven aligned or random nanofiber mesh to create scaffold for the generation of endplate (EP) tissue.
University of Central Oklahoma | Date: 2013-01-31
A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 304.75K | Year: 2015
This award is co-funded by EPSCoR program.
This MRI project is to acquire a computing resource (35 compute nodes each having 2, 8 core Intel Xeon processors, with two nodes having GPU accelerators) that will enable a number of interesting and carefully detailed research efforts at University of Central Oklahoma. Research includes projects on particle transport, stochastic modeling, ecological modeling, bio-informatics and spread of disease. A number of well-developed broadening participation activities in education and research are also proposed.
This project is leveraging the established network of 2- and 4-year colleges for collaborations and is facilitating integration of research and education through training opportunities for students and high school teachers.
Agency: NSF | Branch: Standard Grant | Program: | Phase: IUSE | Award Amount: 299.97K | Year: 2016
This project will fund a student statistical consulting group, called SCHOLAR (Statistical Consulting Help for Organizational Leaders and Academic Researchers). SCHOLAR will give students the opportunity to study statistics while participating in service learning or experiential education projects. It will be an academic year program, staffed by undergraduate students who will work collaboratively on interdisciplinary projects submitted by researchers at the University of Central Oklahoma (UCO) or organizations in the community. Up to 20 students will be directly involved with SCHOLAR each year and hundreds indirectly through high school recruiting visits and project dissemination. High school seniors and undergraduate students will be recruited from a variety of majors and will enter the program in their freshman or sophomore years. The goals of SCHOLAR are (1) to increase the number of undergraduate students majoring or minoring in statistics or mathematics, especially those from underrepresented groups in STEM (e.g. Native Americans and women) and first-generation low-income students; (2) to teach undergraduate students, through faculty and peer mentoring, how to conduct and report research, and to prepare students for careers or graduate study in STEM fields; (3) to contribute to the growing body of research concerning the effects of experiential statistics education on undergraduate students; and (4) to provide statistical consulting services to other faculty at UCO and the community at large.
SCHOLAR will significantly change the current methods of statistics instruction and research, especially with respect to the involvement of recent high school graduates and college underclassmen in experiential statistics education. It will also contribute to the renewed call for improvement in STEM education by providing undergraduate students access to real research and real data. SCHOLAR students will meet with clients as consultants, collect and analyze data, and provide written and oral summaries of their work. They will also be required to present each year at a local and/or national conference. Other SCHOLAR features include student mentoring by peers, faculty, and researchers; teaching opportunities through student-led seminars; and early exposure to a variety of research being conducted both on- and off-campus. The effects of SCHOLAR activities on students will be tracked and evaluated and the outcomes will be reported through publications and presentations at professional meetings. SCHOLAR will be a model program for the use of experiential education to teach statistics, especially at primarily undergraduate institutions. Future plans are to expand the SCHOLAR model to other institutions, and to branch out to incorporate other disciplines including mathematical biology, operations research, and high-performance computing.
Agency: NSF | Branch: Standard Grant | Program: | Phase: RSCH EXPER FOR UNDERGRAD SITES | Award Amount: 396.64K | Year: 2016
This REU Site award to the University of Central Oklahoma (UCO), located in Edmond, Oklahoma, will support the training of eight students for eight weeks during the summers of 2016-2019. This award is supported by both the Division of Biological Infrastructure within the Directorate for Biological Sciences and the Office of International Science and Engineering. Research will be in the Republic of Turkey at Middle East Technical University (Ankara) and Uludað University (Bursa). Students will be selected based upon criteria that includes an essay as to why participation in the project will be important to the students career. The program focuses on the honey bee as a model organism to study pollination dynamics in variable environments, behavioral ecology and comparative psychology, and behavioral and physiological responses to stress. The program begins with a mini-course at UCO that includes Responsible Conduct in Research training. An excursion through northwestern Turkey will acclimate students to research methodology and the customs of the region before groups travel to the campuses at Ankara and Bursa. The program concludes at UCO with group presentations and reflection.
It is anticipated that a total of 32 students, primarily from schools or backgrounds with limited research opportunities, will be trained in the program. Students will not only engage directly in team-based, cutting-edge research but will also have the opportunity to present their results at a national scientific conference. The programs international setting, including experiences throughout the Republic of Turkey, provides an opportunity to learn from a geographic region of great historical significance to human civilization; students will develop enduring professional relationships with faculty and students at the host institutions. Research findings will address global issues, including the causes and effects of Colony Collapse Disorder.
A common web-based assessment tool used by all REU programs funded by the Division of Biological Infrastructure will be used to determine the effectiveness of the training program. Students will be tracked after the program in order to determine their career paths and be asked to respond to an automatic email sent via the NSF reporting system. More information about the program is available by visiting http://www.uco.edu/cms/reu/, or by contacting the PI (Dr. John Barthell at email@example.com) or the co-PI (Dr. Charles Abramson at firstname.lastname@example.org).
Agency: NSF | Branch: Standard Grant | Program: | Phase: RSCH EXPER FOR UNDERGRAD SITES | Award Amount: 251.25K | Year: 2013
The University of Central Oklahoma REU Site Grant will provide an international and integrative biological research experience for at least six undergraduates during eight weeks each summer of 2013-2015. This REU program, centered at Uludag University, near Istanbul and the Sea of Marmara, is designated as a Global Venture Fund Award and supported by the NSFs Offices of International Science and Engineering (OISE) and the Directorates for Biological Sciences (BIO). The research program involves collaboration with scientists at institutions in the United States, Greece, and the Republic of Turkey. Hypotheses are posed in a biogeographic and phylogenetic context, using the honey bee as a model system for understanding the ecological, behavioral, comparative psychological, and molecular biological aspects of invasive species. Prior to and during the program, students will be immersed in mini-courses and discussions that teach ethics and responsible conduct in research and the nature of scientific research. Students are asked to continue their participation beyond the eight-week period of the program, reconvening to present results at a national conference, as well as being offered opportunities to publish research findings. The program will support a generation of scientists who understand the relationship between human diversity and intellectual innovation. Indeed, students participate in enrichment activities that include visiting some of the most significant locations in the history of human civilization: Istanbul, the Ancient City of Troy, the Aegean islands, and the Ancient City of Pergamum. Because many large-scale ecological problems in the United States (including invasive species, parasites, and disease) originate from outside its borders, the diverse and interdisciplinary collaborations in the program help to develop students who can conduct scientific research in an increasingly globalized setting. Student applications are assessed based upon academic performance, letters of recommendation, research aptitude, and the quality of a brief written essay. Students are tracked after the program to understand the impact the experience has on their career paths; assessment is also made during the program with surveys and the REU Common Assessment Tool. The program is supported by funds from the National Science Foundation?s Directorate of Biological Sciences. Additional information can be found at http://cms.uco.edu/REU/, or by contacting the Principal Investigator (Dr. John F. Barthell at email@example.com).
University of Central Oklahoma | Date: 2015-12-29
A process providing a method for production of probiotic functional food products from plant substrates, the method comprising: activation of probiotic bacteria in an agar-agar formulation; formulation of water active plant substrates; culturing and incubation of water active plant substrates with activated probiotic bacteria; cooling and refrigeration.
University of Central Oklahoma | Date: 2014-06-13
A method and apparatus for providing personalized configuration of physical supports for the human body, comprising accepting input including an individuals demographic information, neurological attributes, physical history, operational environment, and outcome or use objectives, processing user input employing an artificial intelligence engine, and then returning guidance and/or control parameters directed to seating adjustment and positioning, including incline angles for wheelchair tilt and recline.